The headline numbers for Marex Group PLC (MRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Although the revenue and EPS for MSG Entertainment (MSGE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

While the top- and bottom-line numbers for Madison Square Garden (MSGS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. (“RxSight” or the “Company”)(NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

MANCHESTER, England--(BUSINESS WIRE)--Manchester United plc (NYSE: MANU) is delighted to announce a new three-year partnership with The Coca-Cola Company, naming Coca-Cola as the club's Official Carbonated Soft Drinks Partner in the United Kingdom and Europe. The partnership will see Coca-Cola headline across matchdays and fan experiences, offering fans the perfect refreshment at Old Trafford and beyond. The agreement includes pouring rights for Coca-Cola, Coca-Cola Zero, Diet Coke, Fanta, Fant.

TRP remains a solid dividend grower, but its valuation has become more elevated, prompting me to enhance income through covered call writing. Rolling our latest covered calls up and out lets me collect option premiums while still participating in potential share price appreciation as well as dividend income. Recent earnings were strong, with increased EBITDA guidance and reduced leverage, but the stock is now trading closer to the upper range of fair value.

MU projects high-teen DRAM demand growth in 2025, fueled by AI-driven applications and record data center sales.

NVDA gains U.S. approval to sell H20 AI chips in China, reopening a key market despite a 15% revenue-sharing requirement.

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.12 per share a year ago.

Euroseas Ltd. (ESEA) came out with quarterly earnings of $4.2 per share, beating the Zacks Consensus Estimate of $3.87 per share.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Earnings season is in full swing and investors are watching closely. For many of those investors, earnings season can be the trigger to make small shifts or even big wholesale changes in portfolios.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against XPLR Infrastructure, LP (“XPLR” or the “Company”) (NYSE: XIFR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.